/

BYSI

BeyondSpring, Inc.Closed

0.6067−0.01 −1.43%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

0.6200

Prev close

0.6155

Day range

0.60120.6445

52-week range

0.56602.44

Volume

53.41K0.06×

Mkt cap

24.95M

P/E ttm

—

Fwd P/E

-1.29

EPS ttm

-0.1800

Div yield

0.00%

Earnings

—

From 52w high

−75.14%

Price Chart

Yahoo Finance · delayed

BYSIOct 12, 2026O 0.5980H 0.6600L 0.5900C 0.6160+0.0100 (+1.65%)Vol 38.00K

SMA 500.7501
SMA 2001.3522

1Y change −64.60% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

BYSI BeyondSpring, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −21.63%
1 month: −19.37%
3 months: −53.68%
6 months: −64.80%
Year to date: −62.21%
1 year: −64.60%

Valuation & ownership

Market cap: 24.95M
Enterprise value: 18.13M
P/E (ttm): —
Forward P/E: -1.29
PEG ratio: —
Price / book: —
Price / sales (ttm): —
EV / EBITDA: -2.16
EPS (ttm): -0.1800
EPS (forward): -0.4700
Beta (5y monthly): -0.21
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 41.12M
Float: 31.95M
Short % of float: 7.17%
Short ratio (days): 4.34
Held by insiders: 17.40%
Held by institutions: 14.77%
Avg volume (3m): 855.75K
50-day average: 0.7501
200-day average: 1.35
52-week change: −64.60%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 40.8
vs 50-day SMA: −17.88%
vs 200-day SMA: −54.44%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 17.11%
Realised vol (20d, ann.): 202.7%
From 52-week high: −74.75%
From 52-week low: +8.83%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About BeyondSpring, Inc.

Yahoo Finance profile

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Sector: Healthcare
Industry: Biotechnology
Employees: 44
Headquarters: Florham Park, NJ, United States
Website: beyondspringpharma.com
Officers

SEAS

Seasonality · BYSI

2017–2026 · monthly returns

Strongest month Aug +22.59%Weakest month Jul −13.32%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-5.5	-12.3	21.5	-7.3	10.5	4.2	-34.3	-46.0	24.0	-21.2			−62.8%
2025	9.8	-5.6	-15.1	21.3	0.3	34.7	-12.8	-16.1	5.2	9.9	6.5	-23.1	+0.0%
2024	8.9	35.7	168.4	-43.7	30.8	-8.7	-19.2	5.2	12.3	-3.7	-12.5	-15.5	+81.1%
2023	37.2	-26.7	-40.7	-13.5	5.3	15.7	-11.0	-14.3	-11.1	23.7	-13.6	5.3	−52.1%
2022	-28.7	-25.4	-8.7	-30.9	-9.9	5.1	-3.5	-5.0	-25.0	-24.5	-22.4	224.1	−58.5%
2021	-0.5	6.9	-14.7	-2.5	-3.9	0.7	-8.8	228.9	-49.7	-12.3	-7.6	-64.5	−62.9%
2020	-2.3	4.9	-19.3	12.0	18.5	-11.3	-26.9	12.7	7.1	10.7	-24.2	9.1	−21.3%
2019	-4.8	0.8	-11.0	-6.3	9.0	45.0	-29.3	7.7	0.3	-34.6	5.2	24.5	−17.3%
2018	0.2	-29.6	25.0	21.0	-13.9	-0.7	-5.8	-8.0	8.9	-24.8	29.0	-22.7	−35.5%
2017				23.6	41.6	22.9	-2.6	-7.8	-4.2	-4.5	-7.6	-10.6	+45.9%

INSD

Insider Activity · BYSI

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Mar 19, 2026	Huang LanChief Executive Officer	Stock Gift at price 0.00 per share.	260.6K	—
Oct 16, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.72 - 1.76 per share.	131.3K	$227.68K
Oct 9, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.77 - 1.81 per share.	13.9K	$24.72K
Oct 6, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.76 - 1.79 per share.	20.2K	$35.97K
Oct 1, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.73 - 1.81 per share.	7.7K	$13.80K
Sep 28, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.66 - 1.75 per share.	1.8K	$3.04K
Sep 23, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.68 - 1.83 per share.	11.8K	$20.75K
Sep 18, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.74 - 1.83 per share.	11.3K	$20.00K
Sep 15, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.84 - 1.88 per share.	4.1K	$7.60K
Sep 10, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.90 - 1.97 per share.	21K	$40.87K
Sep 7, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.82 - 1.93 per share.	9K	$17.20K
Sep 2, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.74 - 1.81 per share.	4.9K	$8.68K
Aug 27, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.78 - 1.81 per share.	4.1K	$7.36K
Aug 24, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.75 - 1.79 per share.	5.7K	$10.12K
Aug 19, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.74 - 2.03 per share.	54.7K	$109.16K
Aug 14, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 2.00 per share.	4.9K	$9.80K
Aug 3, 2025	Decheng Capital China Life Sciences Usd Fund Iii, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 2.18 - 3.23 per share.	394.4K	$1.20M

13F

Investors Holding BYSI

latest 13F filings of 29 followed managers

Investors holding BYSI
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$19.1K	0.00%	10.90K	−1.8%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

BYSI

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

BYSI

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About BeyondSpring, Inc.

Seasonality · BYSI

Insider Activity · BYSI

Congress Trades · BYSI

Investors Holding BYSI

Investors Holding BYSI

Congress Trades · BYSI

Seasonality · BYSI

Insider Activity · BYSI

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About BeyondSpring, Inc.

Earnings & Dividends

News